Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Liabilities and Shareholders Equity (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $492.1 million as the latest value for Q2 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 23.39% to $492.1 million in Q2 2025 year-over-year; TTM through Sep 2025 was $1.6 billion, a 16.65% increase, with the full-year FY2024 number at $576.8 million, up 60.11% from a year prior.
  • Liabilities and Shareholders Equity was $492.1 million for Q2 2025 at Centessa Pharmaceuticals, down from $527.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $609.7 million in Q3 2024 to a low of $360.2 million in Q4 2023.
  • A 4-year average of $488.2 million and a median of $492.1 million in 2025 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: decreased 21.28% in 2023, then soared 61.57% in 2024.
  • Centessa Pharmaceuticals' Liabilities and Shareholders Equity stood at $444.3 million in 2022, then fell by 18.92% to $360.2 million in 2023, then skyrocketed by 60.11% to $576.8 million in 2024, then decreased by 14.68% to $492.1 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Liabilities and Shareholders Equity are $492.1 million (Q2 2025), $527.8 million (Q1 2025), and $576.8 million (Q4 2024).